Graphene-Scaffolded Na₃V₂(PO₄)₃ Microsphere Cathode with High Rate Capability and Cycling Stability for Sodium Ion Batteries

High voltage, high rate, and cycling-stable cathodes are urgently needed for development of commercially viable sodium ion batteries (SIBs). Herein, we report a facile spray-drying method to synthesize graphene-scaffolded Na₃V₂(PO₄)₃ microspheres (NVP@rGO), in which nanocrystalline Na₃V₂(PO₄)₃ is embedded in graphene sheets to form porous microspheres. Benefiting from the highly conductive graphene framework and porous structure, the NVP@rGO material exhibits a high reversible capacity (115 mAh g^–1 at 0.2 C), long-term cycle life (81% of capacity retention up to 3000 cycles at 5 C), and excellent rate performance (44 mAh g^–1 at 50 C). The electrochemical properties of a full Na-ion cell with the NVP@rGO cathode and Sb/C anode are also investigated. The present results suggest promising applications of the NVP@rGO material as a high performance cathode for sodium ion batteries

Additional file 1 of Strategies for identification of somatic variants using the Ion Torrent deep targeted sequencing platform

Supplementary Materials. (PDF 1208 kb

Additional file 3: Table S1. of Real-time monitoring efficiency and toxicity of chemotherapy in patients with advanced lung cancer

Methylation frequency of APC and/or RASSF1A in present study and other 5 articles. (DOCX 80 kb

Additional file 4: Table S2. of Real-time monitoring efficiency and toxicity of chemotherapy in patients with advanced lung cancer

Clinical characteristics of 316 advanced lung cancer patients. (DOCX 18 kb

Additional file 5:Table S3. of Real-time monitoring efficiency and toxicity of chemotherapy in patients with advanced lung cancer

Primers and probes used in duplex qMSP. (DOCX 13.7 kb

Additional file 2: Figure S2. of Real-time monitoring efficiency and toxicity of chemotherapy in patients with advanced lung cancer

Methylation amplification curves for APC or RASSF1A in A549 cells. (A) Methylation amplification curves for APC gene promoter. (B) Methylation amplification curves for RASSF1A gene promoter. The Ct values for APC and RASSF1A gene amplification in A549 cells were close to those of the H460 positive control cells. (TIFF 1393 kb

Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas

<p>Small cell prostate carcinoma (SCPC) morphology is rare at initial diagnosis but often emerges during prostate cancer progression and portends a dismal prognosis. It does not express androgen receptor (AR) or respond to hormonal therapies. Clinically applicable markers for its early detection and treatment with effective chemotherapy are needed. Our studies in patient tumor–derived xenografts (PDX) revealed that AR–negative SCPC (AR⁻SCPC) expresses neural development genes instead of the prostate luminal epithelial genes characteristic of AR–positive castration-resistant adenocarcinomas (AR⁺ADENO). We hypothesized that the differences in cellular lineage programs are reflected in distinct epigenetic profiles. To address this hypothesis, we compared the DNA methylation profiles of AR⁻ and AR⁺ PDX using methylated CpG island amplification and microarray (MCAM) analysis and identified a set of differentially methylated promoters, validated in PDX and corresponding donor patient samples. We used the Illumina 450K platform to examine additional regions of the genome and the correlation between the DNA methylation profiles of the PDX and their corresponding patient tumors. Struck by the low frequency of AR promoter methylation in the AR⁻SCPC, we investigated this region's specific histone modification patterns by chromatin immunoprecipitation. We found that the AR promoter was enriched in silencing histone modifications (H3K27me3 and H3K9me2) and that EZH2 inhibition with 3-deazaneplanocin A (DZNep) resulted in AR expression and growth inhibition in AR⁻SCPC cell lines. We conclude that the epigenome of AR⁻ is distinct from that of AR⁺ castration-resistant prostate carcinomas, and that the AR⁻ phenotype can be reversed with epigenetic drugs.</p

Unsupervised hierarchical clustering of the differentially expressed proteins (P<0.05) between gene expression derived biliary-like and intestinal-like ampullary subgroups.

<p>Unsupervised hierarchical clustering of the differentially expressed proteins (P<0.05) between gene expression derived biliary-like and intestinal-like ampullary subgroups.</p

Figure 2

<p>Unsupervised hierarchical clustering of ampullary adenocarcinoma samples, n = 14 (A).Clinical and molecular characteristics are listed below the figure: group 3 gene expression grouping (black), poor differentiation (black), mucinous histology (black), T4/T3 (black), N1 (black), presence of an adenoma (black), activation mutations in KRAS, BRAF, PI3K (black), MSI-high status (black), CK7+/CK20− (black), CDX-2+ (black), and histological subtype. Overall survival by gene expression derived biliary-like and intestinal-like ampullary subgroups (B).</p

Patient and Tumor Characteristics of Ampullary Validation Dataset.

<p>Patient and Tumor Characteristics of Ampullary Validation Dataset.</p